{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:47:06Z","timestamp":1755222426880,"version":"3.43.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,10]]},"DOI":"10.7759\/cureus.89747","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T23:04:08Z","timestamp":1754867048000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory Ulcerative Colitis Successfully Treated With a Combination of Granulocyte and Monocyte Apheresis and Mirikizumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Tomotaka","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Yoshifuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nodoka","family":"Otabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songde","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese S","year":"2015","unstructured":"Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015, 12:537-45. 10.1038\/nrgastro.2015.135","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al.. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019, 381:1215-26. 10.1056\/NEJMoa1905725","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr, et al.. Efficacy and safety of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020, 158:2123-38. 10.1053\/j.gastro.2020.01.047","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00012.x","article-title":"Therapeutic leukocytapheresis for inflammatory bowel disease: a review of technical and clinical aspects","volume":"7","author":"Saniabadi AR","year":"2003","unstructured":"Saniabadi AR, Hanai H, Takeuchi K, et al.. Therapeutic leukocytapheresis for inflammatory bowel disease: a review of technical and clinical aspects. Transfus Apher Sci. 2003, 7:1-15. 10.1046\/j.1526-0968.2003.00012.x","journal-title":"Transfus Apher Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.453","article-title":"An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment","volume":"104","author":"Sakuraba A","year":"2009","unstructured":"Sakuraba A, Motoya S, Watanabe K, et al.. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009, 104:2990-5. 10.1038\/ajg.2009.453","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v11.3.43","article-title":"Selective granulocyte and monocyte apheresis in inflammatory bowel disease: its past, present and future","volume":"12","author":"Chen XL","year":"2020","unstructured":"Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: its past, present and future. World J Gastrointest Pathophysiol. 2020, 12:43-56. 10.4291\/wjgp.v11.3.43","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22091","article-title":"Adsorptive cytapheresis in ulcerative colitis: a non-pharmacological therapeutic approach revisited","volume":"38","author":"Vernia F","year":"2023","unstructured":"Vernia F, Viscido A, Latella G. Adsorptive cytapheresis in ulcerative colitis: a non-pharmacological therapeutic approach revisited. J Clin Apher. 2023, 38:746-54. 10.1002\/jca.22091","journal-title":"J Clin Apher"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21260","article-title":"Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study","volume":"16","author":"Yamamoto T","year":"2010","unstructured":"Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010, 16:1905-11. 10.1002\/ibd.21260","journal-title":"Inflamm Bowel Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad070","article-title":"Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies","volume":"5","author":"Sands BE","year":"2023","unstructured":"Sands BE, Feagan BG, Hunter Gibble T, et al.. Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies. Crohns Colitis 360. 2023, 5:otad070. 10.1093\/crocol\/otad070","journal-title":"Crohns Colitis 360"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens G","year":"2023","unstructured":"D'Haens G, Dubinsky M, Kobayashi T, et al.. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023, 388:2444-55. 10.1056\/NEJMoa2207940","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.6801","article-title":"Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis","volume":"7","author":"Tanida S","year":"2015","unstructured":"Tanida S, Mizoshita T, Nishie H, et al.. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis. Intern Med. 2015, 7:884-9. 10.2169\/internalmedicine.51.6801","journal-title":"Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4625","article-title":"Combination therapy with ustekinumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis","volume":"13","author":"Tanida S","year":"2021","unstructured":"Tanida S, Ozeki K, Kanno T, et al.. Combination therapy with ustekinumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis. J Clin Med Res. 2021, 13:510-4. 10.14740\/jocmr4625","journal-title":"J Clin Med Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00117","article-title":"Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study","volume":"20","author":"Poylin VY","year":"2022","unstructured":"Poylin VY, Serrato JC, Pastrana Del Valle J, Feuerstein JD. Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study. Intest Res. 2022, 20:72-7. 10.5217\/ir.2020.00117","journal-title":"Intest Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5302-20","article-title":"Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis","volume":"59","author":"Nakamura M","year":"2020","unstructured":"Nakamura M, Yamamura T, Maeda K, et al.. Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis. Intern Med. 2020, 59:3009-14. 10.2169\/internalmedicine.5302-20","journal-title":"Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2024.01.002","article-title":"Selective granulocyte\u2011monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: experience in a tertiary hospital","volume":"47","author":"Su\u00e1rez Ferrer C","year":"2024","unstructured":"Su\u00e1rez Ferrer C, Martin-Arranz E, Mart\u00edn-Arranz MD. Selective granulocyte\u2011monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: experience in a tertiary hospital. Gastroenterol Hepatol. 2024, 47:721-6. 10.1016\/j.gastrohep.2024.01.002","journal-title":"Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastre.2024.04.052","article-title":"Combination of granulocyte-monocyte apheresis and tofacitinib: multicentre and retrospective study","volume":"47","author":"Rodr\u00edguez\u2011Lago I","year":"2024","unstructured":"Rodr\u00edguez\u2011Lago I, Herrera\u2011deGuise C, Bosc\u00e1\u2011Watts M, et al.. Combination of granulocyte-monocyte apheresis and tofacitinib: multicentre and retrospective study. Gastroenterol Hepatol. 2024, 47:727-33. 10.1016\/j.gastre.2024.04.052","journal-title":"Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr5165","article-title":"Efficacy and safety of upadacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction for intractable ulcerative colitis","volume":"16","author":"Tanida S","year":"2024","unstructured":"Tanida S, Sasoh S, Otani T, et al.. Efficacy and safety of upadacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction for intractable ulcerative colitis. J Clin Med Res. 2024, 16:256-63. 10.14740\/jocmr5165","journal-title":"J Clin Med Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77641","article-title":"Successful treatment of refractory ulcerative colitis with 5-aminosalicylic acid intolerance and biologic therapy resistance using combined granulocyte and monocyte adsorptive apheresis","volume":"17","author":"Tanaka T","year":"2025","unstructured":"Tanaka T, Hirano D, Ishimaru S, Arataki K. Successful treatment of refractory ulcerative colitis with 5-aminosalicylic acid intolerance and biologic therapy resistance using combined granulocyte and monocyte adsorptive apheresis. Cureus. 2025, 17:e77641. 10.7759\/cureus.77641","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393004-refractory-ulcerative-colitis-successfully-treated-with-a-combination-of-granulocyte-and-monocyte-apheresis-and-mirikizumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T23:04:09Z","timestamp":1754867049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393004-refractory-ulcerative-colitis-successfully-treated-with-a-combination-of-granulocyte-and-monocyte-apheresis-and-mirikizumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.89747","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,10]]}}}